New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment

Bluebird Bio Inc BLUE presented new results for betibeglogene autotemcel (beti-cel), investigational gene therapy for β-thalassemia (beta-thal) who require regular red blood cell (RBC) transfusions.

  • New data demonstrate that adult and pediatric β-thalassemia patients can produce normal or near-normal total hemoglobin levels, remain transfusion-free, and achieve stable iron markers through up to seven years of follow-up (n=3). 
  • "In the analysis published in New England Journal of Medicine (NEJM), 91% of patients, including six of seven patients under the age of 12, achieved transfusion independence as well as improvement in erythropoiesis and liver iron concentrations," said Professor Franco Locatelli, lead author.
  • Beti-cel stabilized iron markers in patients who achieved transfusion independence and could stop iron chelation (n=20/34), with markers of iron management improving toward normal.
  • Adult, adolescent, and pediatric patients experienced early and sustained improvement in health-related quality-of-life measures from baseline across Phase 3 studies.
  • Related Link: Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA.
  • Price Action: BLUE shares are up 9.93% at $9.85 during the premarket session on the last check Monday.
  • Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralASH21beta-thalassemiaBriefsgene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!